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325 Early detection of glucose derangement in children with Cystic
Fibrosis
V. Raia1, F. De Gregorio1, A. Sepe1, I. De Simone1, E. Mozzillo1, G. Valerio2,
A. Franzese1. 1Department of Pediatrics, University Federico II, Naples, Italy;
2University Parthenope, Naples, Italy
Patients and Methods: 22/83 children <10 yrs with CF (12 Females, mean age
89.4 months, range 29–130) were selected for glucose intolerance on the basis of
fasting hyperglycaemia (FH), stress hyperglycaemia (IH) or increased HbA1c. All
patients had pancreatic insufﬁciency and severe genotype. Patients were classiﬁed
as CF related diabetes (CFRD) with FH/ without FH, impaired glucose tolerance
(IGT), normal glucose tolerance (NGT) on the basis of OGTT, according to
American Diabetes Association diagnostic criteria. For patients with glucose values
>140mg/dl at any time between T30 and T90 but with normal values at T120
CFRD was conﬁrmed by CGMS (AGT).
Results: 18/22 pts were investigated for increased value of HbA1c, while 4/22 for
IH. 12/22 were classiﬁed as AGT, 0/22 as IGT, 1/22 as CFRD without FH, 2/22
as CFRD-FH. 7/22 were NGT. The mean value of HbA1c of children with glucose
derangement was 6% (range 5.3−7) compared to mean value of 5.7% (range 5.5−6)
in NGT. A worse pulmonary status was detected in the ﬁrst group. 5/15 showed
failure to thrive.
Discussion: we report an increased prevalence of glucose intolerance in CF patients
<10 years of age, suggesting that OGTT may underestimate this complication in
children. CGSM is conﬁrmed to be a more sensitive method of diagnosis in cases
with high intermediate glucose levels during OGTT. Furthermore, our data suggest
that HbA1c reference range could be revised respect to the age. A strict control
of glucose tolerance is recommended early in infancy, especially in presence of
risk factors for CFRD such as severe genotype, female sex, exocrine pancreatic
insufﬁciency, increasing number of pulmonary exacerbations and failure to thrive.
326 Early diagnosis of glucose intolerance and/or diabetes in children
with cystic ﬁbrosis
K. Walicka1, D. Sands1, K. Zybert1, R. Piotrowski1. 1Pediatrics, IMiD, Warsaw,
Poland
The aim of our study was to evaluate the prevalence of abnormalities of glucose
tolerance in children with CF aged 5 to 19 years, to determine the most useful
indexes in early diagnosis of glucose intolerance or diabetes in the preclinical
period, to ﬁnd the risk factors inﬂuencing the development of CFRD (Cystic Fibrosis
Related Diabetes).
Methods: Children (n = 90, mean age 11.7±4.1 years) with CF, not previously
diagnosed with diabetes underwent 3-hour oral glucose tolerance testing (OGTT).
All subjects with CF were clinically stable.
Result: Abnormal glucose metabolism (AGM) was diagnosed in 14 (15.6%)
patients. Diabetes without fasting hyperglycemia (CFRD without FH) was detected
in 3 (3.3%) and impaired glucose tolerance (IGT) in 11 (12.2%) children. Two boys
with IGT (18.2%) had impaired fasting glucose (IFG). The prevalence of CFRD
was 6.6% and IGT 11.2%. The higher glucose area under curve (AUC), early
insulin secretion defect and insulin resistance were better associated with clinical
status than the conventional glucose tolerance classiﬁcation based on OGTT. The
diagnosis of abnormalities of glucose tolerance was correlated with indexes of
glucose metabolism; glycemia during OGTT; Cmax, Tmax and AUC for glucose;
peak time of insulin level (Tmax ins); indexes: insulin sensitivity, early and late
insulin release.
We conclude that OGTT is a useful investigation in the diagnosis of abnormalities
of glucose tolerance in CF. Hyperglycemia may not be the most sensitive index of
insulin deﬁciency in the diagnosis of CFRD.
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Introduction: The UK CF Trust Diabetes Working Group (2004) recommend
blood glucose monitoring (BGM) in all inpatients during a respiratory exacerbation
(RE) and that patients should be considered for insulin if blood glucose levels are
persistently raised.
A previous audit demonstrated inconsistent and suboptimal inpatient BGM in
our unit resulting in inadequate assessment and management of glycaemic sta-
tus during a RE. This led to the development and audit of an inpatient BGM
policy/documentation.
Aims: Re-audit CF inpatient BGM using the unit policy/documentation. Highlight
those requiring insulin.
Methods: All CF patients admitted with a RE in Nov & Dec 2008 underwent
BGM. The policy recommends monitoring for the ﬁrst 48hrs of admission: pre
and 2hrs post breakfast, lunch and evening meal, before bed, pre, 2hrs into and
post enteral feed (EF). All patients with persistently raised BG levels >10mmol/L
were assessed for insulin by the Diabetes Nurse (DN). Results were compared with
previous audits.
Results: See the table.
Conclusion: Hyperglycaemia was evident during a RE regardless of prior glucose
tolerance status. The unit BGM policy has resulted in more effective assessment
and management of glycaemic and clinical status.
Mean % frequency of BGM
Pre meal Post meal BB Pre EF 2hrs into EF Post EF
Audit 2008 84 46 91 88 75 100
Audit 2007 69 34 47 60 65 35
Pre policy audit 2006 31 12 40 60 70 30
328 Perks and pitfalls of interstitial glucose monitoring – early
experience from an ongoing pilot study
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Background: Oral Glucose Tolerance Testing (OGTT) with subsequent home
capillary blood glucose (BG) monitoring does not always reﬂect true ‘real-life’
handling of glucose in CF. Continual Glucose Monitoring Studies (CGMS) may
have a role in providing a more complete picture.
Objectives: We compared OGTT, determining normal (NGT), impaired (IGT) or
diabetic glucose tolerance (DGT) to CGMS.
Methods: 12 adult subjects with stable CF disease had a 3 day home CGMS,
recording 4 BG levels daily for calibration. During the 3 day CGMS they attended
clinic for OGTT. They also recorded dietary intake, exercise and any relevant
symptoms.
Results: 10/12 completed the protocol (2 sensors failed before OGTT), 2/10 were
unsuitable for analysis due to lack of calibration data. Within the 2 hour period
of the OGTT, blood glucose values and CGMS agreed for NGT(n = 3), IGT(n = 1)
and DGT(n = 4). The 4 patients with NGT and IGT had interim glucose excursions
into the diabetic range by CGMS during the OGTT. The 3 patients with NGT had
CGMS traces showing ‘diabetic lifestyles’ outwith the OGTT; these highs and lows
were often not evident from BG values alone. The patient with IGT had normal
continual glucose levels outside this 2 hour test period with their usual diet and
daily activities.
Conclusions: OGTT is helpful for categorising people, but there is not a good
correlation between this ‘snapshot’ of glucose handling and true glycaemic control
within patients’ usual lifestyles. CGMS, however, requires calibration by frequent
BG checks, with which several patients had difﬁculty, and sensor failure may
occasionally occur.
More subjects are being recruited to validate CGMS and fully explore glycaemic
control in our patients in stable and acute disease.
